This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Neurodegenerative Therapies. Top assignee: Acadia Pharmaceuticals Inc.. Active years: 2003-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Lyngby, DK (2003 - 2007)
- Ballerup, DK (2009 - 2010)
- Vaerloese, DE (2012)
- Glostrup, DK (2004 - 2017)
- Vaerloese, DK (2010 - 2020)
Company Filing History:
Years Active: 2003-2020
Areas of Expertise:
Title: Innovations in Neuropharmacology: The Contributions of Allan K Uldam
Introduction: Allan K Uldam, based in Vaerloese, Denmark, is a prominent inventor with a remarkable portfolio of 19 patents. His groundbreaking work focuses on therapeutic advancements targeting neurodegenerative diseases, particularly through the development of innovative pharmacological agents.
Latest Patents: One of Uldam's latest patents explores selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative conditions. In his research, he presents behavioral pharmacological data demonstrating the in vivo efficacy of a novel compound. This compound, described by formula (I), has shown promise in reversing MK-801 induced locomotor behaviors, indicating potential efficacy as an anti-psychotic. Additionally, it demonstrates efficacy in an MPTP primate model of dyskinesias, suggesting its potential as an anti-dyskinesia agent. Moreover, Uldam's findings support the hypothesis that 5HT2A/2C receptor inverse agonism may lead to effective treatments for Parkinson's disease and other related human neurodegenerative diseases, including psychosis.
Career Highlights: Allan K Uldam has made significant contributions to the field of neuropharmacology through his work at Acadia Pharmaceuticals Inc. His career is marked by his commitment to advancing therapeutic options for patients with challenging neurodegenerative conditions.
Collaborations: Throughout his career, Uldam has collaborated with esteemed professionals such as Carl-Magnus A Andersson and David M Weiner, further enhancing the impact of his innovations in neuropharmacology.
Conclusion: Allan K Uldam's innovative research and developments in the field positions him as a key figure in addressing neurodegenerative diseases. His dedication to discovering novel therapeutics holds promise for new treatments that could significantly improve the lives of those affected by these conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile